With Atrial Fibrillation (AFib), Change Can Come in
a Matter of Moments
In 2019, about 8 million people in the United States are projected to be diagnosed with AFib, and that number is expected to grow to an estimated 12 million people by 2030.1 Given the expected growing number of people
with AFib, this could mean there may
be more people at a higher risk
of stroke as a result.2
Why Is AFib Awareness Important?
If you or a loved one have undiagnosed AFib, life may change in a matter of moments. With AFib cases increasing, now can be a good time to learn about AFib’s connection to stroke and understand the importance of diagnosis.
After you understand if you're potentially at risk for AFib, you can be better prepared to bring the topic up with your doctor.
What Is the Connection Between AFib and Stroke?
In a patient with AFib, the upper chambers of the heart beat irregularly, meaning the blood cannot effectively move into the lower chambers of the heart, which may lead to blood pooling in the heart, potentially forming a clot. If that blood clot enters the bloodstream and gets stuck in an artery that leads to the brain, it can cause a life-threatening or debilitating stroke.3
Increasing awareness about AFib and its relationship to stroke will take collaboration between health-care professionals, caregivers, and patients. Read this perspective and more from a group of health-care
leaders and patient advocates in this article on The Atlantic.
Alliance—Bristol-Myers Squibb and Pfizer
The Bristol-Myers Squibb-Pfizer Alliance established an awareness initiative in late 2018, called Matter of Moments: Recognizing AFib-Stroke Risk. Why “Matter of Moments?” Because in a matter of moments, the lives of individuals, as well as their family and friends, can be affected by AFib-related stroke. On the other hand, AFib may also be detected in a matter of moments as a part of routine medical care.
The Alliance created the Matter of Moments initiative to help raise awareness of AFib, its connection to stroke, and the importance of a timely AFib diagnosis. We are doing this by collaborating with expert health-care professionals and advocacy organizations so that patients and health-care providers can be better prepared for a future where AFib may be more prevalent.
This global alliance combines Bristol-Myers Squibb’s long-standing strengths in cardiovascular disease
with Pfizer’s global scale and expertise in this field.
Learn More About AFib
The American Heart Association (AHA) is a national voluntary health agency dedicated to fighting heart disease and stroke. Learn more about AFib from the AHA.
Bristol-Myers Squibb and Pfizer do not endorse these organizations. The information included on this site and the links provided by Bristol-Myers Squibb and Pfizer are meant for informational purposes only and are not meant to replace a physician’s medical advice.
- Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol. 2013;112(8):1142–1147.
- Centers for Disease Control and Prevention (CDC). Atrial fibrillation fact sheet. https://www.cdc.gov/dhdsp/data_statistics/ fact_sheets/fs_atrial_fibrillation.htm. Accessed October 10, 2018.
- National Heart, Lung, and Blood Institute (NHLBI). Atrial fibrillation. https://www.nhlbi.nih.gov/health-topics/atrial-fibrillation. Accessed March 1, 2019.